Adial Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 8731 https://www.adialpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals Inc

Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial - Jun 27th, 2022 1:16 pm
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence - Jun 14th, 2022 2:48 pm
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Jun 14th, 2022 1:55 pm
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH - May 19th, 2022 1:25 pm
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results - May 16th, 2022 1:25 pm
Maravai LifeSciences Reports First Quarter 2022 Financial Results - May 5th, 2022 8:05 pm
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders - May 4th, 2022 1:15 pm
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy - Apr 6th, 2022 11:47 am
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - Mar 22nd, 2022 1:15 pm
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder - Feb 24th, 2022 2:15 pm
Adial Pharmaceuticals Announces Closing of $10 Million Financing - Feb 16th, 2022 2:26 pm
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering - Feb 11th, 2022 2:00 pm
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma - Feb 9th, 2022 2:25 pm
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04 - Jan 24th, 2022 2:25 pm
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year? - Jan 12th, 2022 2:40 pm
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference - Jan 10th, 2022 2:03 pm
Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share - Dec 22nd, 2021 2:25 pm
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer - Dec 8th, 2021 2:25 pm
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer - Nov 29th, 2021 2:00 pm
REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments - Nov 17th, 2021 2:42 pm